Table of Contents Exhibit 99.2 REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION (UNAUDITED) June 30, 2024 1 Table of Contents REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION (UNAUDITED) June 30, 2024 TABLE OF CONTENTS | UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, | Page | | --- | --- | | 2024, IN U.S. DOLLARS: | | | Condensed consolidated interim statements of comprehensive income (loss) | 3 | | Condensed consolidated in ...

A transformed RedHill: Numerous potential catalysts Strengthened cash balance and control over our destiny following the Termination Agreement with Movantik Acquisition Co. and others: Executing on our plan to ensure a value-driven focus, operational efficiency and financial streamlining with a low cost-base U.S. government collaborations: Developing a promising, advancing and largely financially de-risked pipeline via U.S. government and other collaborations Addressing substantial and underserved indicatio ...

Neuroblastoma is rare but is the most common infancy malignancy with a median age of diagnosis of 17 months. In the U.S., it accounts for up to around 10% of all childhood cancer cases and 15% of pediatric cancer-related deaths[1],[2] Orphan Drug designation provides for seven-years' marketing exclusivity should opaganib be approved in neuroblastoma and may confer additional benefits such as accelerated development and review times, potential grant funding and possible tax credits The neuroblastoma market i ...

Core Viewpoint - RedHill Biopharma has launched Talicia, the first approved low-dose rifabutin-containing all-in-one combination treatment for H. pylori infection, in the UAE, which opens up eligibility for additional milestone payments and royalties for the company [1][2]. Group 1: Product Launch and Market Impact - Talicia is now available by prescription in the UAE for adults with H. pylori infection, which affects 41% of the UAE population and over 50% of the global adult population [1][3]. - The launch of Talicia triggers RedHill's eligibility for potential milestone payments, minimum sales payments, and tiered royalties up to mid-teens on net sales [1][2]. - Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists for H. pylori treatment [1]. Group 2: Medical Need and Efficacy - H. pylori is a significant public health concern, being a major risk factor for gastric cancer, with traditional clarithromycin-based therapies showing declining effectiveness [2][4]. - A 2021 study indicated only 68.5% eradication with clarithromycin-based therapy, which dropped to 32% in patients with resistant H. pylori [2][3]. - Talicia demonstrated an 84% eradication rate in a pivotal Phase 3 study, significantly higher than the 58% rate in the active comparator arm [5][6]. Group 3: Product Composition and Resistance - Talicia is a fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), specifically designed to combat high resistance rates of H. pylori to other antibiotics [4][5]. - Minimal to zero resistance to rifabutin was detected in the pivotal Phase 3 study, highlighting its effectiveness [5][6]. Group 4: Company Overview - RedHill Biopharma is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases, promoting Talicia for H. pylori and Aemcolo for travelers' diarrhea [9]. - The company is engaged in various late-stage development programs targeting multiple indications, including COVID-19 and oncology [9].

The global obesity-diabetes drugs market is projected to be worth around $100 billion by 2034[1] – largely driven by Glucagon-like peptide-1 (GLP-1) inhibitors like Novo Nordisk's Ozempic® and Wegovy® and Eli Lilly's Trulicity® and Mounjaro® and sodium glucose cotransporter-2 (SGLT2) inhibitors such as Boehringer Ingelheim's Jardiance® -- Positive results from multiple in vivo studies show the impact of sphingosine kinase-2 (SPHK2) inhibition in various models of metabolic disease, supporting the potential ...

TEL AVIV, Israel and RALEIGH, N.C., Aug. 16, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it plans to implement a ratio change of the Company's American Depositary Shares (ADSs) to its non-traded ordinary shares from the current ratio of one (1) ADS representing four hundred (400) ordinary shares to a new ratio of one (1) ADS representing ten thousand (10,000) ordinary shares. The anticipated first date o ...

One of today's biggest movers in the biotech sector is RedHill Biopharma (NASDAQ:RDHL), a little-known specialty player in the space focusing on gastrointestinal and infectious diseases. Today, RDHL stock is up more than 75% in early afternoon trading on an announcement from the company that it has seen positive results for a key Phase 3 study. This study focused on patients suffering from Chron's disease, assessing how its RHB-104 treatment would compare to the current standards of care in the industry. Im ...

Newly published in the peer-reviewed journal Antibiotics, the 331-patient Phase 3 Crohn's disease study data shows the primary endpoint of clinical remission at week 26 was achieved, with high statistical significance, in 36.7% (61/166) of orally administered RHB-104 plus standard of care (SoC) patients, compared to 22.4% (37/165) of placebo plus SoC patients (p=0.0048); Safety profile similar to placebo. Study conducted across more than 100 sites The advanced stage clinical data demonstrating the potential ...

About RedHill Biopharma Forward Looking Statements [1] Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: www.Talicia.com. TEL-AVIV, Israel and RALEIGH, NC, July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the signing of a Global Termination Agreement with Movantik Acquisition Co., Valinor Pharma ...

Core Viewpoint - RedHill Biopharma Ltd. has mutually decided with Cosmo Technologies Ltd. to terminate their exclusive U.S. license agreement for Aemcolo, a treatment for traveler's diarrhea, effective October 8, 2024 [3][6][11]. Company Overview - RedHill Biopharma is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases, promoting drugs such as Talicia® for H. pylori infection and Aemcolo® for traveler's diarrhea [11]. - The company is engaged in late-stage development programs including opaganib for multiple indications and RHB-107 for symptomatic COVID-19, with external funding covering the RHB-107 arm of a Phase 2 trial [11]. License Agreement Details - The License Agreement for Aemcolo was initially dated October 17, 2019, and will officially terminate on October 8, 2024, after which all rights will revert to Cosmo [3][6]. - RedHill will cease any commercialization efforts for Aemcolo immediately upon termination of the License Agreement [6]. Future Development Plans - RedHill's key clinical programs include: - Opaganib, a first-in-class oral SPHK2 selective inhibitor, targeting indications such as Acute Radiation Syndrome and COVID-19 [11]. - RHB-107, an oral serine protease inhibitor in late-stage development for non-hospitalized symptomatic COVID-19 [11]. - Other programs targeting gastrointestinal diseases and oncology [11].